Xcout Intel
Promontory Therapeutics
Promontory Therapeutics Inc. is a privately held, clinical-stage pharmaceutical company founded in 2010 and headquartered in New York, NY. The firm focuses on small molecule immunotherapy.
Subscribe to see Promontory Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Promontory Therapeutics at a glance
Promontory Therapeutics is a drug discovery company headquartered in United States. Its most recent funding round, Series A, raised $37M in December 2021. Xcout tracks 7 named people at Promontory Therapeutics, including Johan Baeck (EXECUTIVE VICE PRESIDENT & CMO).
Promontory Therapeutics leadership
- Johan BaeckEXECUTIVE VICE PRESIDENT & CMO
- Robert E. FallonPRESIDENT & CEO
- R. Matthew PriceEXECUTIVE VICE PRESIDENT & COO
- Tyler AmesSVP, RESEARCH & DEVELOPMENT
- Hélène A. SheaVP, CHEMISTRY MANUFACTURING & CONTROLS
- Aamena ChaudhryDIRECTOR, REGULATORY AFFAIRS
1 more named person on record for Promontory Therapeutics, with roles, board committees and tenure — see the full roster →
Promontory Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $37M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Promontory Therapeutics competitors
A few of Promontory Therapeutics's closest competitors — see the full list of competitors and alternatives →
Peptomyc is a clinical-stage biotechnology company headquartered in Barcelona, Spain, specializing in the development of protein and peptide therapeutics for cancer.
KayoThera, Inc. is an early-stage, preclinical therapeutics company headquartered in Seattle, Washington. The firm focuses on developing first-in-class, oral, small molecule treatments.
Ahammune Biosciences is an India-based drug-discovery biotechnology company focused on developing small-molecule therapies for immune-mediated and inflammatory diseases. It serves pharmaceutical and healthcare markets by advancing novel immunomodulatory drug candidates toward clinical development.
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients. Founded in 2024, the company is based in Morris Plains, New Jersey.
Get Promontory Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Promontory Therapeutics in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access